Evidence Vault

The Future of Evidence-Based Peptide Use: Circles Data StrategyPeptide therapeutics are reshaping modern medicine, offering targeted treatments for conditions ranging from metabolic disorders to aesthetic concerns. These short chains of amino acids function as hormones, neurotransmitters, and signaling molecules, giving them a unique precision in interacting with the body’s receptors. This precision has driven explosive market growth, projected to reach USD 84 billion by 2034, with North America leading and Asia Pacific showing the fastest expansion.However, the promise of peptides is constrained by the limitations of traditional randomized controlled trials. While RCTs remain the gold standard for regulatory approval, their narrow inclusion criteria produce homogenous datasets that fail to represent real-world patient diversity. Older adults, patients with multiple comorbidities, and diverse ethnic groups are often excluded — leaving critical gaps in understanding how peptides perform across broad populations. Furthermore, RCTs rarely provide long-term data, undermining confidence in durability, safety, and patient-reported outcomes over years of use.Data fragmentation compounds this issue. Manual spreadsheets and siloed tools lead to inconsistent, incomplete, and error-prone information, which slows clinical innovation and complicates payer or regulatory decisions. The peptide industry urgently needs a new paradigm: structured, longitudinal, verifiable real-world evidence (RWE).Circles: A Strategic Solution RegenMed’s Circles platform delivers a scalable approach to collect and validate high quality RWE. By combining physician-facing inCytes™ and patient-facing Benchmarc™ platforms, Circles aggregates standardized datasets without interrupting normal clinical flow. They produce FDA-compliant, auditable datasets that can inform regulatory submissions, post-market surveillance, and payer negotiations.The benefits extend to multiple stakeholders. Pharmaceutical and biotech companies can sponsor Circles to generate evidence for new indications, demonstrate long-term value, and refine treatment protocols. Clinicians gain insights to optimize care and monetize their expertise while positioning themselves as thought leaders. Payers and regulators gain confidence in cost-effectiveness and safety, while patients receive more effective, personalized peptides-based therapies.Applications and Use CasesCritical areas for peptide RWE include metabolic disorders, where GLP-1 receptor agonists like semaglutide revolutionize weight loss and diabetes care; sports medicine and injury recovery, where BPC-157 accelerates healing; and anti-aging/aesthetics, where compounds like GHK-Cu improve skin elasticity and appearance.Specific Circle Datasets — for instance, correlating outcomes over two years of BPC-157 effects on ligament healing – can materially help close scientific knowledge gaps and support clinical decisions.The peptide therapeutics market is also evolving alongside manufacturing innovations such as continuous production methods that reduce waste and costs. As synthesis accelerates, new peptides will reach clinics faster, amplifying the need for robust real-world validation. Without such evidence, promising treatments risk delayed adoption or regulatory challenges.The Path ForwardEmbracing Circles-based RWE is more than a competitive edge — it’s a strategic imperative. By closing the gap between controlled trials and real-world practice, Circles create a dynamic feedback loop that informs clinical decisions, accelerates innovation, and drives commercial success. For patients, this means safer, more effective therapies tailored to their needs. For the industry, it signals a shift from simply selling molecules to delivering comprehensive, evidence-backed solutions. Those who adopt this model early will define the future of peptide therapeutics.

Real-World Evidence: Unlocking the Full Potential of MSC TherapyMesenchymal Stem Cells (MSCs) represent one of the most versatile and promising tools in regenerative medicine. Their ability to modulate the immune system, reduce inflammation, and orchestrate tissue repair has led to investigations across a wide spectrum of conditions — from osteoarthritis and autoimmune disease to pioneering neurological applications.Yet despite this therapeutic promise, clinical adoption of MSCs has been slowed by a critical barrier: evidence.The Challenge: Evidence Gaps in Regenerative MedicineRandomized controlled trials (RCTs) have long been the gold standard for clinical research. They are designed to minimize bias and deliver clear results in highly controlled settings.But for regenerative therapies, especially cell-based interventions, RCTs often fall short.Short timeframes limit the ability to capture long-term outcomes in chronic or progressive conditions.Strict inclusion criteria mean that many real-world patients — those with comorbidities or complex disease patterns — are excluded.High costs make it difficult to run large-scale, long-duration studies necessary to validate MSC durability.As a result, key questions remain unanswered: Which MSC sources perform best? What dosing regimens deliver sustainable results? How do outcomes differ across patient subgroups?The Solution: Real-World Evidence (RWE)Real-world evidence, derived from data collected during routine clinical practice, offers a transformative way forward. Unlike RCTs, RWE can:Capture outcomes over long time horizons, aligning with the chronic nature of many conditions MSCs target.Reflect the diversity of real clinical populations, not just highly selected trial cohorts.Provide practical insights into dosing, protocols, and durability that matter in day-to-day practice.Regulators, payers, and clinicians alike are increasingly turning to RWE to inform decisions. For regenerative medicine, it is not just complementary to traditional trials — it is essential.How RegenMed Circles Advances MSC EvidenceAt RegenMed, we’ve developed the Circles platform to address the unique challenges of MSC research and care. Circles are physician-led, collaborative frameworks designed to generate validatable, clinically meaningful RWE with minimal burden on providers and patients.Key features include:Structured data capture: Standardized observational protocols ensure clinical depth and comparability.Patient engagement: Tools like Benchmarc™ integrate patient-reported outcomes into the dataset.Collaboration across sites: Physicians pool outcomes data, achieving statistical power and generalizability.Physician ownership: Providers retain control and value from the data they generate.The result is high-quality, auditable datasets that not only advance clinical understanding but also inform regulators, support reimbursement, and accelerate adoption of MSC therapies.Looking AheadThe global MSC market is projected to reach $7.2 billion by 2030, reflecting the immense promise of these therapies. But to fulfill that promise, evidence generation must keep pace with innovation.By combining physician expertise, patient engagement, and rigorous data frameworks, RegenMed Circles is helping to close the evidence gap. Together, we can move MSC therapy from potential to practice — and set the standard for how regenerative medicine proves its value in the real world.Сontact usDownload the White Paper "Circles For Mesenchymal Stem Cell Care And Research", Sept 2025

The Moment For PT Is Here — Now Let’s Make It MeasurablePhysical therapy has moved from a purely post-injury service to a true first-line option for neuromusculoskeletal conditions. Utah’s Senate Bill 196 is emblematic: it explicitly recognizes PT as primary care under insurance law, removing referral friction and signaling confidence in PTs as initial evaluators and managers of back pain, sprains, and joint complaints. The military’s decades-long experience using PTs in primary care roles further demonstrates that this model is safe and reduces downstream utilization.This shift isn’t just philosophical; it’s economic. For common MSK problems, PT often matches surgical outcomes without the costs and risks of invasive care or long-term medication. The “Comparative Economic Value of Physical Therapy” table lists substantial net savings — for example, ~$14k for knee osteoarthritis vs. steroid injections and ~$39k for carpal tunnel syndrome vs. surgery — illustrating how early, non-invasive care changes the cost curve.The profession’s educational foundation supports this evolution. DPT programs blend rigorous biomedical science with extensive clinical rotations, preparing PTs to function as autonomous clinicians and collaborators in complex, multidisciplinary pathways. The result is a workforce ready for first contact care — and ready to generate practice-embedded evidence.The Missing Piece: Trustworthy Real-World Evidence (RWE)Randomized trials remain crucial, but they rarely capture everyday PT practice: diverse patients, real adherence patterns, comorbidities, and social context. Legacy RWE sources — claims, registry feeds, heterogeneous EHR extracts — are often fragmented, retrospectively assembled, and hard to verify back to the primary source. PT’s own outcomes registry (PTOR) struggled with participation and incentives, reminding us that centralized “after-the-fact” approaches stall without shared value and low-friction workflows.If PT is to win durable reimbursement as a first-contact, value-based service, the field needs RWE that is:Verifiable to origin (auditable to the moment of care and the patient);Clinically rich (functional metrics, PROMs, adherence, and course-of-care details);Interoperable (FHIR-compatible, payer-ready, guideline-ready);Equity-aware (SDOH captured alongside outcomes, not as an afterthought);Governed for trust (patient ownership, transparent consent, and federated analytics).Why Circles Fits PT Like A GloveCircles is RegenMed’s protocol-driven RWE platform designed to meet these exact requirements. In physical therapy, Circles functions as a “learning loop” at the point of care: 1. Protocol-driven capture at the source: Observational Protocols (OPs) specific to MSK conditions structure what’s collected: baseline impairment, functional goals, exercise prescriptions, progression, clinician observations — plus patient-reported outcomes and engagement signals. Data is FHIR-compatible and auditable. 2. Patient ownership + federated governance: Anonymized data remains under patient control, and analytics can operate in a federated model across sites. This avoids the participation and incentive pitfalls that limited prior registries. 3. Equity by design: Circles embeds SDOH and access variables directly into PT-tailored protocols, making disparities measurable and actionable for health systems and payers. 4. AI-ready structure: Because Circles data are standardized and verified, predictive models (e.g., likelihood of recovery plateaus, adherence risk, visit intensity needed) become clinically actionable — unlike models trained on inconsistent, retrospective data.Concrete PT Use Cases Where Circles Pays Off1) First-contact triage and pathway optimization: With Circles-guided protocols, clinics capture functional baselines and early improvement trajectories in visit 1–2, producing verifiable evidence that supports “PT-first” pathways and reduces unnecessary imaging and specialist visits. 2) Value-based contracts that reward real outcomes: Circles harmonizes case-mix variables, visit intensity, and PROM improvement, enabling contracts that pay for progress, not just units.3) Precision rehabilitation and adherence support: Circles integrates with wearables, computer-vision ROM tracking, and VR-based engagement tools. Feeding their signals into Circles converts them into verified evidence on adherence and outcomes.4) Continuous quality improvement across clinics: Multi-site groups can compare protocol fidelity, session mix, and time-to-milestone by diagnosis and therapist — without shipping raw PHI.Implementation Blueprint For PT LeadersStart where the value is obvious.Pick 3–5 high-volume MSK lines (e.g., acute LBP, knee OA, rotator cuff, carpal tunnel, pelvic floor). Turn existing eval templates into Circles OPs with required PROMs, visit cadence, and discharge criteria.Wire data at the moment it’s created.Map clinic workflows so clinicians enter outcomes once, at the point of care. Connect patient apps for home exercise check-ins and symptom tracking.Prove it with a 90-day payer pilot.Negotiate a micro-contract on one condition (e.g., acute LBP). Report monthly from Circles on time-to-meaningful improvement, return-to-work, and total cost vs. usual care.Measure equity, not just averages.Disaggregate outcomes by SDOH variables captured in Circles. Use these insights to justify transportation vouchers, extended hours, or digital check-ins.Make AI work for clinicians. Train interpretable models on Circles data (e.g., probability of dropout, predicted visits to achieve MCID). Surface these as point-of-care nudges clinicians can trust.Why this matters system-wideFor policymakers and payers, Circles provides the verification layer that links “PT-first” policy with real outcomes and spend reductions. For health systems, it operationalizes integrated MSK pathways while producing payer-ready, equity-aware evidence. For PT practices, it turns daily work into durable advantages: better contracts, fewer denials, and a reputation for outcomes that patients feel and actuaries can price. For innovators, it’s the interoperable substrate where sensors, VR, and AI become not just engaging — but provably effective.ConclusionPhysical therapy has earned the right to be a first-contact pillar of modern healthcare. To secure that role at scale, PT needs evidence that is trustworthy, comparable, and rooted in the lived reality of care. Circles delivers exactly that — patient-owned, protocol-driven, FHIR-compatible datasets that make value visible, equity measurable, and innovation verifiable. It doesn’t just generate more data; it produces better evidence — the kind that moves guidelines, reimbursement, and outcomes in the same direction.